IP Library Granted Patent US 8,252,306
Granted Patent B2
US 8,252,306 · App. 13/279,949 · Granted Aug 28, 2012

Process for preparing a semi-solid delivery vehicle comprising granisetron

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,252,306
App. No.
13/279,949
Granted
Aug 28, 2012
Kind
B2
Abstract

A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Claims (38)

1. A process for the preparation of a pharmaceutical composition comprising:

(A) a semi-solid delivery vehicle, comprising:

(i) a polyorthoester consisting of formula I

where:

R* is ethyl;

n is an integer of 5 to 1000; and

A is R 1 or R 3 where

R 1 is:

where:

p is an integer of 1 to 20;

R 5 is hydrogen; and

R 6 is:

where:

s is an integer of 0 to 10;

R 3 is:

where:

x is an integer of 0 to 30;

in which about 0.05-30 mol percent of the A units are of the formula R 1 ; and

(ii) polyethylene glycol monomethyl ether; and

(B) granisetron in an amount of 1-5 weight % of the composition; the process comprising mixing the components (A)(i) and (A)(ii) and (B) to form the composition.

2. The process of claim 1 , wherein the process comprises:

(1) warming the polyorthoester;

(2) dissolving the granisetron in the polyethylene glycol monomethyl ether to form a solution; and

(3) mixing the polyorthoester and the solution to obtain a homogeneous mixture.

3. The process of claim 1 , wherein the polyethylene glycol monomethyl ether has a molecular weight between 200 and 4000.

4. The process of claim 3 , wherein the polyethylene glycol monomethyl ether comprises polyethylene glycol monomethyl ether 550.

5. The process of claim 4 , wherein the total concentration of the polyethylene glycol monomethyl ether is 5-60 weight % of the composition.

6. The process of claim 1 , wherein the polyorthoester is a reaction product of 3,9-di(ethylidene)-2,4,8,10-tetraoxaspiro[5.5 ] undecane (DETOSU), triethylene glycol (TEG) and triethylene glycol diglycolide (TEG-diGL).

7. The process of claim 1 , wherein the composition comprises 78.4 weight % polyorthoester, 19.6 weight % polyethylene glycol monomethyl ether and 2 weight % granisetron.

8. The process of claim 1 , wherein p is an integer of 1 to 7 in a portion of the units of formula I.

9. The process of claim 1 , wherein x is 2 in a portion of the units of formula I.

10. The process of claim 1 , wherein s is 2 in a portion of the units of formula I.

11. The process of claim 1 , wherein the total concentration of the polyethylene glycol monomethyl ether is 5% to 80% weight percent of the composition.

12. The process of claim 1 , wherein the mixing is performed at a temperature between about 5° C. and 200° C.

13. The process of claim 1 , wherein:

the polyorthoester is a reaction product of 3,9-di(ethylidene)-2,4,8,10-tetraoxaspiro[5.5]undecane (DETOSU), triethylene glycol (TEG) and triethylene glycol diglycolide (TEG-diGL); and

the polyethylene glycol monomethyl ether has a molecular weight between 200 and 4000.

14. The process of claim 1 , wherein about 0.1-25 mol percent of the A units are of the formula R 1 .

Assignments (4)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 9, 2023
From: HERON THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 064546/0453 →
RELEASE OF SECURITY INTEREST Recorded Mar 25, 2021
From: TANG CAPITAL PARTNERS, LP
To: HERON THERAPEUTICS, INC.
Reel/Frame 055725/0523 →
SECURITY INTEREST Recorded Aug 30, 2016
From: HERON THERAPEUTICS, INC.
To: TANG CAPITAL PARTNERS, LP
Reel/Frame 039590/0239 →
CHANGE OF NAME Recorded Feb 3, 2014
From: A.P. PHARMA, INC.
To: HERON THERAPEUTICS, INC.
Reel/Frame 032153/0273 →